You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 20, 2025

Ampicillin/ampicillin trihydrate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for ampicillin/ampicillin trihydrate and what is the scope of patent protection?

Ampicillin/ampicillin trihydrate is the generic ingredient in fourteen branded drugs marketed by Parke Davis, Aurobindo Pharma, Belcher Pharms, Chartwell Rx, Ivax Sub Teva Pharms, Lederle, Mylan, Purepac Pharm, Sandoz, Strides Pharma, Vitarine, Wyeth Ayerst, Pfizer, Bristol, Apothecon, Bristol Myers Squibb, Glaxosmithkline, Endo Operations, Teva, and Cosette, and is included in forty-four NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for ampicillin/ampicillin trihydrate
Recent Clinical Trials for ampicillin/ampicillin trihydrate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4

See all ampicillin/ampicillin trihydrate clinical trials

Pharmacology for ampicillin/ampicillin trihydrate

US Patents and Regulatory Information for ampicillin/ampicillin trihydrate

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Apothecon PRINCIPEN '500' ampicillin/ampicillin trihydrate CAPSULE;ORAL 050056-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Bristol POLYCILLIN ampicillin/ampicillin trihydrate CAPSULE;ORAL 050310-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Wyeth Ayerst OMNIPEN (AMPICILLIN) ampicillin/ampicillin trihydrate CAPSULE;ORAL 060624-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Wyeth Ayerst OMNIPEN (AMPICILLIN) ampicillin/ampicillin trihydrate FOR SUSPENSION;ORAL 060625-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Wyeth Ayerst OMNIPEN (AMPICILLIN) ampicillin/ampicillin trihydrate FOR SUSPENSION;ORAL 060625-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Pfizer PFIZERPEN-A ampicillin/ampicillin trihydrate FOR SUSPENSION;ORAL 062049-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Lederle AMPICILLIN TRIHYDRATE ampicillin/ampicillin trihydrate CAPSULE;ORAL 062208-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

Market Dynamics and Financial Trajectory for Ampicillin/Ampicillin Trihydrate

Market Overview

The ampicillin and ampicillin trihydrate market is poised for significant growth, driven by several key factors. Here are the main dynamics and financial projections for this market.

Growing Demand for Antibiotics

The demand for ampicillin is increasing due to the rising prevalence of bacterial infections such as respiratory tract infections, urinary tract infections, and meningitis. This trend is expected to continue, driven by the need for effective antibiotics to combat these infections[4].

Impact of COVID-19

The COVID-19 pandemic has heightened the demand for antibiotics like ampicillin, not only for primary bacterial infections but also for managing secondary infections and as part of combination therapies in hospitals and healthcare facilities treating COVID-19 patients. This surge reflects increased awareness and concern about bacterial infections amid the pandemic, potentially leading to a notable uptick in prescriptions and consumption of ampicillin[1].

Antibiotic Resistance

The growing issue of antibiotic resistance has intensified the focus on effective antibiotic drugs like ampicillin. Healthcare authorities are emphasizing the need to control antibiotic resistance, which is driving the demand for ampicillin and other broad-spectrum antibiotics[1].

Market Size and Growth Projections

Ampicillin Market

The global ampicillin market is forecast to reach $385.82 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 3.5% during the period 2024-2030. This growth is driven by the increased demand for antibiotics and the role of ampicillin in treating various bacterial infections[1].

Ampicillin Trihydrate Market

The ampicillin trihydrate market is valued at USD 150 billion in 2023 and is expected to reach USD 211.07 billion by 2031, growing at a CAGR of 5% from 2024 to 2031. This market growth is attributed to the broad-spectrum efficacy of ampicillin trihydrate in treating a variety of bacterial illnesses[3].

Price Trends

Recent Price Movements

Ampicillin prices have shown an upward trend in recent quarters. The high demand for penicillin, the feedstock material for ampicillin, and the rise in infections during the cold winter months have contributed to this increase. Despite strict regulations, the prices have seen positive but limited fluctuations[2].

Future Projections

Analysts predict that ampicillin prices will continue to rise in the coming quarters due to sustained high demand and positive market sentiments. The production of raw materials, particularly in China, and improvements in supply chains and logistics will influence the price trend[2].

Market Segmentation

Indications

The ampicillin market is segmented based on indications such as meningitis, respiratory tract infections, urinary tract infections, gastrointestinal infections, and others. The respiratory tract infections segment dominates the market due to the high prevalence of these infections globally[4].

Route of Administration

Ampicillin can be administered through various routes, including oral, intramuscular, and intravenous. The market analysis shows significant revenue and volume growth across these administration methods, with each method catering to different clinical needs[1].

Distribution Channel

The market is segmented by distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies dominate the market due to the widespread use of ampicillin in hospitals to treat various bacterial infections[4].

Geographical Regions

The market is analyzed across geographical regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America is expected to dominate the global market due to high healthcare spending and a strong emphasis on infection control methods[4].

Financial Trajectory

Revenue Growth

The revenue growth of the ampicillin market is driven by increasing government healthcare spending, a stronger emphasis on infection control, and the proper use of antibiotics. The market is expected to surpass $238.29 billion by 2031, growing at a CAGR of 3.30% from 2022 to 2031[4].

Cost and Production Factors

The production costs of ampicillin are influenced by the cost of raw materials, particularly penicillin, and logistical challenges. The rise in the cost of raw materials, especially from China, and disruptions in supply chains have impacted the production and pricing of ampicillin[2].

Generic Formulations and Pharmaceutical Innovations

The availability of affordable generic formulations and improvements in pharmaceutical manufacturing techniques are further propelling the growth of the ampicillin trihydrate market. These factors enhance accessibility and affordability, contributing to the market's financial trajectory[3].

Key Takeaways

  • Growing Demand: The increasing prevalence of bacterial infections is driving the demand for ampicillin.
  • COVID-19 Impact: The pandemic has heightened the demand for antibiotics like ampicillin.
  • Antibiotic Resistance: The focus on controlling antibiotic resistance is driving the demand for effective antibiotics.
  • Market Size: The ampicillin market is expected to reach $385.82 million by 2030, while the ampicillin trihydrate market is projected to reach $211.07 billion by 2031.
  • Price Trends: Ampicillin prices are expected to rise due to high demand and positive market sentiments.
  • Market Segmentation: The market is segmented by indications, route of administration, distribution channels, and geographical regions.

FAQs

Q: What is driving the growth of the ampicillin market?

The growth of the ampicillin market is driven by the increasing prevalence of bacterial infections, the impact of the COVID-19 pandemic, and the need to address antibiotic resistance.

Q: How is the ampicillin trihydrate market expected to grow?

The ampicillin trihydrate market is expected to grow at a CAGR of 5% from 2024 to 2031, reaching $211.07 billion by 2031.

Q: What are the main indications for ampicillin?

The main indications for ampicillin include meningitis, respiratory tract infections, urinary tract infections, and gastrointestinal infections.

Q: How do supply chain disruptions affect ampicillin prices?

Supply chain disruptions, particularly in the production of raw materials from China, have led to an increase in ampicillin prices due to constrained supplies relative to high demand.

Q: What role do generic formulations play in the ampicillin market?

Generic formulations of ampicillin enhance accessibility and affordability, contributing to the market's growth by making the drug more available to a broader patient population.

Sources

  1. IndustryARC: Ampicillin Market Size Report, 2024-2030.
  2. Procurement Resource: Ampicillin Price Trend, Index, News, Chart, Database.
  3. Market Research Intellect: Ampicillin Trihydrate Market Size & Share Analysis.
  4. GlobeNewswire: Ampicillin Market Size Worth US$ 238.29 billion by 2031.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.